HOME >> BIOLOGY >> NEWS
Critical therapeutics is awarded U.S. patents for methods to diagnose and treat inflammatory disease

Cambridge, Massachusetts, December 2, 2002 -- Critical Therapeutics, Inc. (CTI) today announced that it has been awarded three U.S. patents covering methods to diagnose, predict the severity of and treat serious inflammatory diseases including sepsis, a bloodstream infection that is the nation's tenth leading cause of death.

The patents, which were issued by the United States Patent and Trademark Office, relate to a protein within the High Mobility Group (HMGB) family of nuclear proteins. This protein, HMGB1, has been identified as an important mediator of the body's inflammatory response to infection, ischemia and injury. Increased levels of HMGB1 have been implicated in sepsis and other major inflammatory diseases including rheumatoid arthritis.

"Therapies targeting HMGB1 can potentially afford significant benefits to critically ill patients stricken with serious systemic inflammatory disease," said Walter Newman, Ph.D., CTI's chief scientific officer. "As a result, these patents give CTI a strong intellectual property foothold as we move forward with discovery and development initiatives related to this protein."

U.S. patent number 6,468,533 B1, "Antagonists of HMGB1 for Treating Inflammatory Conditions," provides a pharmaceutical composition comprised of an antibody that binds HMGB1. The antibody, in turn, is believed to dramatically reduce the "cytokine cascade," or overproduction, of HMGB1 that triggers sepsis and other inflammatory diseases.

U.S. patent number 6,448,223 B1, "Antagonists of HMGB1 for Treating Inflammatory Conditions," covers a method of administering antibodies to treat the inflammatory illness. These antibodies neutralize the pro-inflammatory effect of HMGB1.

U.S. patent number 6,303,321 B1, "Methods of Diagnosing Sepsis," provides for a method to diagnose the disease and to predict its severity by measuring the concentration of HMGB1 in the serum.

The Society of Critical Care Medicine def
'"/>

Contact: Scott Solomon
ssolomon@investorrelations.com
617-542-5300
Sharon Merrill Associates, Inc.
2-Dec-2002


Page: 1 2

Related biology news :

1. Critically endangered monkey species plummets more than 50 percent since 1994
2. Save The Tiger Fund announces alliance with the Critical Ecosystem Partnership Fund
3. Critical Therapeutics announces issuance of US patent for novel anti-inflammatory technology
4. Medimmune and Critical Therapeutics to co-develop treatments for severe inflammatory diseases
5. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
6. Critical early-defense trigger in plants found
7. Researchers, Regulators, Industry, Consumer Advocates Gather to Discuss Critical Issues Facing the Pharmaceutical Industry
8. Study Furthers Understanding Of Critical Alzheimers Disease Gene
9. Gene Once Thought To Program Ovarian Development Instead Found To Be Critical For Production Of Sperm
10. UF Researchers: Gene Therapy Replaces Critical Protein In Animal Model Of Often-Fatal Lung-Liver Disease
11. Columbia Researchers Synthesize Compound With Possible Link To MacularDegeneration; Work Is Critical To Pinpointing Causes Of Disease, Scientists Say

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/6/2019)... ... June 05, 2019 , ... ... exclusive financial advisor to Pathologists Bio-Medical Laboratories (PBM) on its recent acquisition by ... pathology platform that provides services to more than one dozen hospitals and surgery ...
(Date:6/4/2019)... ... 04, 2019 , ... Most preclinical EEG visualization platforms offer ... usually based on variations of amplitude, frequency or spike train detection. In the ... to the complexity and variability of the signal, and automation tools are used ...
(Date:5/31/2019)... ... May 29, 2019 , ... FileWave, ... and mobile, announces the launch of version 13.1. The new version extends FileWave’s ... API, and supports Apple’s spring release functionality. Version 13.1 builds on FileWave’s version ...
Breaking Biology News(10 mins):
(Date:5/31/2019)... ... 29, 2019 , ... For many years, the primary forms of cancer treatment ... therapies. Advances in immuno-oncology have led to the advent of Chimeric Antigen Receptor T ... cell receptors known as “CARs”. The CAR enables the final product to produce chemicals ...
(Date:5/31/2019)... ... May 30, 2019 , ... Object ... announce the strategic acquisition of Metabiologics, Inc., a globally recognized leader in the ... ownership and commercialization rights to a full spectrum of botulinum neurotoxins, as well ...
(Date:5/21/2019)... ... May 21, 2019 , ... DuPont Nutrition & Biosciences (DuPont) ... Africa Brewing Conference dedicated to sharing brewing knowledge, strengthening relationships and discussing best ... supported through a partnership with “Ethiopia Invest”, will run through May 23, 2019, ...
(Date:5/14/2019)... EGG HARBOR TOWNSHIP, N.J. (PRWEB) , ... May ... ... premier manufacturer of custom built, helium-based leak testing instruments for the Pharmaceutical, Biotechnology, ... a completely new Heliumleak.com company website. The redesigned website aims to improve LDA’s ...
Breaking Biology Technology:
Cached News: